CANbridge: A bridge to China
By Erin McCallister
Senior Editor
To view the entire article click here.
Many small biotechs in the U.S. and Europe do not have the resources to develop their programs in China in parallel with Western territories, leading to a five- to eight-year lag before a Chinese launch.
CANbridge Life Sciences Ltd. plans to in-license candidates from these companies for China and elsewhere in East Asia as part of a global development strategy for its biotech partners.
This acid can causes an unica-web.com cialis 25mg uncomfortable burning sensation anywhere from stomach to throat. The generic version of purchase levitra online is generally cheaper compared to branded versions of the medication. Some healthy old men levitra best price enjoy sexual pleasure for long by withholding ejection of semen for sufficiently long period of time during love making. This medication has great role to enhance generic tadalafil tablets men’s Erection Quality? Kamagra has been the most prescribed drug for men’s erection problem.
CANbridge wants to get the programs to patients in China faster and believes its executive team can help small biotechs develop their programs in China in parallel with an in-house Western development program.
Two of CANbridge’s executives have experience taking programs through the clinic and to market in China from time spent working at Genzyme China, a division of Genzyme Corp., which was acquired by Sanofi in 2011.
CEO James Xue was the founding general manager of Genzyme China. Crystal Xu, head of clinical development, was Genzyme China’s director of medical and
regulatory affairs.
To view the entire article click here.